Dinesh Pashankar, MD, MBA
ProfessorCards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Regional Director, Ambulatory Services, Yale Medicine
Director, Pediatric IBD program, Pediatrics
Contact Info
Pediatric Gastroenterology & Hepatology
333 Cedar Street, PO Box 208064
New Haven, CT 06520-8064
United States
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Regional Director, Ambulatory Services, Yale Medicine
Director, Pediatric IBD program, Pediatrics
Contact Info
Pediatric Gastroenterology & Hepatology
333 Cedar Street, PO Box 208064
New Haven, CT 06520-8064
United States
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Regional Director, Ambulatory Services, Yale Medicine
Director, Pediatric IBD program, Pediatrics
Contact Info
Pediatric Gastroenterology & Hepatology
333 Cedar Street, PO Box 208064
New Haven, CT 06520-8064
United States
About
Titles
Professor
Regional Director, Ambulatory Services, Yale Medicine; Director, Pediatric IBD program, Pediatrics
Biography
Dr. Pashankar completed his basic medical training in India and in the UK. He completed fellowship training in Pediatric Gastroenterology at BC Children's Hospital in Vancouver, Canada. He has MBA in healthcare from Yale School of Management and has expertise in process and quality improvement.
His clinical and research interest is in inflammatory bowel disease in children. He is the director of Yale Pediatric Inflammatory Bowel Disease Program. He runs a multidisciplinary Inflammatory Bowel disease clinic at Yale New Haven Children's Hospital in New Haven. He has published a number of clinical studies in quality improvement, pediatric gastroenterology and inflammatory bowel diseases. He has presented his work in many national and international conferences.
In addition, he has an active administrative role in Yale medicine. As a medical director of Yale Clinical Optimization Service, he evaluated ambulatory operation of pediatric and adult medical and surgical specialties, resulting in improvement in patient workflow, revenue , patient and provider satisfaction. He is a medical director of Yale Medicine ambulatory services and oversees 40 Yale Medicine clinics in Fairfield county, New Haven and shoreline regions.
Appointments
Pediatric Gastroenterology & Hepatology
ProfessorPrimary
Other Departments & Organizations
Education & Training
- MBA
- Yale School of Management, Healthcare (2018)
- Fellow
- British Columbia's Children's Hospital, Canada (1999)
- Senior Registrar
- St Bartholomew's Hospital, London (1996)
- MD
- Poona University (1990)
- Resident
- Sassoon General Hospital, Pune, India (1989)
Research
Overview
Medical Research Interests
ORCID
0000-0003-0815-8809
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Uma Phatak
Sandra Escalera, MD, FAAP, FACG
Arik Alper, MD
Babar Khokhar, MD, MBA, FAAN (Neurology)
Raffaella Morotti, MD
Ajay Malhotra, MBBS, MD, MMM, FACR
Inflammatory Bowel Diseases
Publications
2024
HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's Disease.
Adler J, Galanko J, Ammoury R, Benkov K, Bousvaros A, Boyle B, Cabrera J, Chun K, Dorsey J, Ebach D, Firestine A, Gulati A, Herfarth H, Jester T, Kaplan J, Leibowitz I, Linville T, Margolis P, Minar P, Molle-Rios Z, Moses J, Olano K, Pashankar D, Pitch L, Saeed S, Samson C, Sandberg K, Steiner S, Strople J, Sullivan J, Wali P, Kappelman M. HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's Disease. The American Journal Of Gastroenterology 2024 PMID: 39423015, DOI: 10.14309/ajg.0000000000003135.Peer-Reviewed Original ResearchConceptsHLA-DQA1*05Anti-drug antibodiesDQA1*05Anti-drug antibody developmentTreatment failureCrohn's diseaseAnti-TNFPositive patientsDevelopment of anti-drug antibodiesAnti-TNF treatment failureTumor necrosis factor antagonistsIndicator of treatment failureAnti-TNF monotherapyPediatric Crohn's diseaseIncreased treatment failureTrial of childrenYears of ageRandomized trial of childrenOral methotrexatePositive participantsRisk stratificationPediatric dataRandomized trialsIncreased riskPrimary outcomeLow Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn’s Disease
Moses J, Adler J, Saeed S, Firestine A, Galanko J, Ammoury R, Bass D, Bass J, Bastidas M, Benkov K, Bousvaros A, Cabrera J, Chun K, Dorsey J, Ebach D, Gulati A, Herfarth H, Ivanova A, Jester T, Kaplan J, Kusek M, Leibowitz I, Linville T, Margolis P, Minar P, Molle-Rios Z, Niklinska-Schirtz B, Olano K, Osaba L, Palomo P, Pashankar D, Pitch L, Samson C, Sandberg K, Steiner S, Strople J, Sullivan J, Tung J, Wali P, Wohl D, Zikry M, Boyle B, Kappelman M. Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn’s Disease. Inflammatory Bowel Diseases 2024, izae239. PMID: 39418336, DOI: 10.1093/ibd/izae239.Peer-Reviewed Original ResearchAltmetricConceptsTherapeutic drug levelsPatients treated with adalimumabPatients treated with infliximabHigher drug levelsAnti-TNF levelsMedian drug levelsTreatment failureCombination therapyReduce treatment failureDrug levelsLD-MTXLow-dose oral methotrexateAssociated with treatment failureCrohn's diseaseMonotherapy to combination therapyRisk of treatment failureAnti-tumor necrosis factorEffects of combination therapyCombination therapy armMaintenance of remissionAssociated with reduced riskPediatric Crohn's diseasePost hoc analysisAdalimumab initiationMaintenance therapyImplementation and evaluation of an electronic consult program at a large academic health system
Arora A, Fekieta R, Spatz E, Roy B, Marco K, Sharifi M, Pashankar D, Khokhar B. Implementation and evaluation of an electronic consult program at a large academic health system. PLOS ONE 2024, 19: e0310122. PMID: 39264980, PMCID: PMC11392322, DOI: 10.1371/journal.pone.0310122.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsAcademic health systemHealth systemEConsult programBenefits of eConsultEffective implementation strategiesPrimary careElectronic consultationSpecialist cliniciansSpecialty cliniciansEngaging leadershipHigh satisfactionImplementation strategiesCapture satisfactionIncrease accessConsultation programProcess outcomesEConsultsQuality assurance mechanismsSurgical specialtiesSpecialtyQuantitative dataMulti-method approachCliniciansSatisfactionProgramHigh Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn’s Disease
Ebach D, Jester T, Galanko J, Firestine A, Ammoury R, Cabrera J, Bass J, Minar P, Olano K, Margolis P, Sandberg K, Linnville T, Kaplan J, Pitch L, Steiner S, Bass D, Moses J, Adler J, Gulati A, Wali P, Pashankar D, Ivanova A, Herfarth H, Wohl D, Benkov K, Strople J, Sullivan J, Tung J, Molle-Rios Z, Saeed S, Bousvaros A, Kappelman M. High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn’s Disease. The American Journal Of Gastroenterology 2024, 119: 1110-1116. PMID: 38445644, PMCID: PMC11150092, DOI: 10.14309/ajg.0000000000002741.Peer-Reviewed Original ResearchCitationsAltmetricConceptsHigher body mass indexNormal body mass indexPediatric Crohn's diseaseBody mass indexAnti-TNF levelsInfliximab initiationTrough levelsTreatment failureObese patientsMass indexTime-to-treatment failureCrohn's diseaseResponse to anti-TNF therapyAssociated with treatment failureMonotherapy to combination therapyBody mass index groupsBody mass index categoriesPrescribed anti-TNFProactive drug monitoringAdalimumab-treated patientsDrug trough levelsAnti-TNF treatmentAnti-TNF therapyInfliximab trough levelsWeight-based dosing
2023
Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn’s Disease: A Pragmatic Randomized Trial
Kappelman M, Wohl D, Herfarth H, Firestine A, Adler J, Ammoury R, Aronow J, Bass D, Bass J, Benkov K, Tobi C, Boccieri M, Boyle B, Brinkman W, Cabera J, Chun K, Colletti R, Dodds C, Dorsey J, Ebach D, Entrena E, Forrest C, Galanko J, Grunow J, Gulati A, Ivanova A, Jester T, Kaplan J, Kugathasan S, Kusek M, Leibowitz I, Linville T, Lipstein E, Margolis P, Minar P, Molle-Rios Z, Moses J, Olano K, Osaba L, Palomo P, Pappa H, Park K, Pashankar D, Pitch L, Robinson M, Samson C, Sandberg K, Schuchard J, Seid M, Shelly K, Steiner S, Strople J, Sullivan J, Tung J, Wali P, Zikry M, Weinberger M, Saeed S, Bousvaros A. Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn’s Disease: A Pragmatic Randomized Trial. Gastroenterology 2023, 165: 149-161.e7. PMID: 37004887, PMCID: PMC10330864, DOI: 10.1053/j.gastro.2023.03.224.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPediatric Crohn's diseaseNecrosis factor inhibitorsPatient-reported outcomesAdverse eventsTreatment failureCombination therapyCrohn's diseaseSerious AEsFactor inhibitorsTumor necrosis factor inhibitorsAnti-drug antibody developmentAnti-TNF monotherapyCombination therapy armCrohn's disease therapyMethotrexate combination therapyTolerable safety profileLow-dose methotrexateMore adverse eventsSerious adverse eventsAnti-drug antibodiesPragmatic Randomized TrialDisease therapyLoss of responseOral methotrexateTherapy armUse, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric‐Onset IBD Cohort
Kaplan J, Liu C, King E, Bass J, Patel A, Tung J, Chen S, Lissoos T, Candela N, Saeed S, Colletti R, Network I, Adler J, Baron H, Cabrera J, Dorsey J, Dykes D, Ebach D, Garin‐Laflam M, Gold B, Grunow J, Higuchi L, Jester T, Lapsia S, Leibowitz I, Linvlle T, Morhardt T, Moses J, Moulton D, Nasiri‐Blomgren S, Niklinska‐Schirtz B, Ogunmola N, Palomo P, Park K, Pashankar D, Pasternak B, Radano M, Samson C, Sandberg K, Schaefer M, Shashidhar H, Steiner S, Sullivan J, Tomer G, Verstraete S. Use, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric‐Onset IBD Cohort. Journal Of Pediatric Gastroenterology And Nutrition 2023, 76: 566-575. PMID: 36804501, PMCID: PMC10097486, DOI: 10.1097/mpg.0000000000003734.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCrohn's diseaseUlcerative colitisLoss of responseFirst biologicSubsequent biologicsBiologic agentsBiologic medicationsBiologic treatmentAnti-tumor necrosis factor agentsUpper gastrointestinal tract involvementGastrointestinal tract involvementNecrosis factor agentsActive Crohn's diseaseFirst biologic agentIBD cohortInitial biologicSecond biologicTract involvementCorticosteroid useFactor agentsPediatric IBDBiologic initiationDisease courseUnivariate analysisSevere diseaseAnalysis of Failure Rates for COVID-19 Entrance Screening at a US Academic Medical Center
Roberts S, Faruq R, Wilkinson A, Pashankar D, Russi M, Khokhar B, Martinello R. Analysis of Failure Rates for COVID-19 Entrance Screening at a US Academic Medical Center. JAMA Internal Medicine 2023, 183: 84-86. PMID: 36441528, PMCID: PMC9706395, DOI: 10.1001/jamainternmed.2022.5426.Peer-Reviewed Original ResearchCitationsAltmetric
2022
Isolated Terminal Ileitis in Children
Alper A, Bennett A, Rottmann D, Morotti R, Escalera S, Phatak U, Pashankar D. Isolated Terminal Ileitis in Children. Journal Of Pediatric Gastroenterology And Nutrition 2022, 76: 338-342. PMID: 36729703, DOI: 10.1097/mpg.0000000000003679.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCrohn's diseaseTerminal ileitisAbnormal C-reactive protein levelsC-reactive protein levelsBowel wall thickeningLong-term outcomesRadiological evidenceRadiological featuresSevere inflammationPediatric literatureHigh prevalenceIleitisWall thickeningProtein levelsChildrenPrevalenceAdultsColonoscopyInflammationEndoscopicHistologicDiseaseMonths
2021
Use of Patient-Reported Outcomes Measurement Information System Pediatric Measures as Clinical Trial Endpoints: Experience from a Multicenter Pragmatic Trial in Children with Crohn’s Disease
Miller T, Schuchard J, Carle A, Forrest C, Kappelman M, Group T, Adler J, Ammoury R, Bass D, Bass J, Benkov K, Bousvaros A, Boyle B, Cabrera J, Colletti R, Dorsey J, Ebach D, Firestine A, Gulati A, Hoffenberg E, Jester T, Kaplan J, Kugathasan S, Kusek M, Leibowitz I, Linville T, Margolis P, Minar P, Rios Z, Moses J, Palomo P, Pappa H, Pashankar D, Saeed S, Samson C, Sandberg K, Steiner S, Strople J, Sullivan J, Tung J, Wali P. Use of Patient-Reported Outcomes Measurement Information System Pediatric Measures as Clinical Trial Endpoints: Experience from a Multicenter Pragmatic Trial in Children with Crohn’s Disease. The Journal Of Pediatrics 2021, 242: 86-92.e3. PMID: 34740588, PMCID: PMC8882140, DOI: 10.1016/j.jpeds.2021.10.053.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPROMIS pediatric measuresMulticenter pragmatic trialCrohn's diseasePediatric measuresClinical trialsDisease activityPain interferencePragmatic trialPediatric patient-reported outcome measuresPatient-reported outcome measuresLower PRO scoresOutcomes Measurement Information System (PROMIS) pediatric measuresPRO score changesSteroid-free remissionPediatric Crohn's diseaseChronic pediatric illnessPragmatic clinical trialsClinical trial endpointsUse of patientPediatric patientsStudy endpointClinical outcomesPRO scoresTrial endpointsPRO endpoints
2020
Continued Statural Growth in Older Adolescents and Young Adults With Crohn’s Disease and Ulcerative Colitis Beyond the Time of Expected Growth Plate Closure
Gupta N, Liu C, King E, Sylvester F, Lee D, Boyle B, Trauernicht A, Chen S, Colletti R, Adler J, Ali S, Al-Nimr A, Ayers T, Baron H, Beasley G, Benkov K, Cabrera J, Cho-Dorado M, Dancel L, Di Palma J, Dorsey J, Gulati A, Hellmann J, Higuchi L, Hoffenberg E, Israel E, Jester T, Kiparissi F, Konikoff M, Leibowitz I, Maheshwari A, Moulton D, Moses J, Ogunmola N, Palmadottir J, Pandey A, Pappa H, Pashankar D, Pasternak B, Patel A, Quiros J, Rountree C, Samson C, Sandberg K, Schoen B, Steiner S, Stephens M, Sudel B, Sullivan J, Suskind D, Tomer G, Tung J, Verstraete S. Continued Statural Growth in Older Adolescents and Young Adults With Crohn’s Disease and Ulcerative Colitis Beyond the Time of Expected Growth Plate Closure. Inflammatory Bowel Diseases 2020, 26: 1880-1889. PMID: 31968095, DOI: 10.1093/ibd/izz334.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsInflammatory bowel diseaseGrowth plate closureUlcerative colitisCrohn's diseaseAge 15 yearsPlate closureStatural growthHeight gainNutrition Examination SurveyFinal adult heightHeight velocity curvesTotal height gainBowel diseasePediatric patientsExamination SurveyPatient transitionsNational HealthAdult carePatientsDisease statusAdult heightDiseaseYoung adultsGrowth plateRadiographic closure
Academic Achievements & Community Involvement
honor International Achievement Award
International AwardNIMS UniversityDetails12/27/2016India
Clinical Care
Overview
Dinesh S. Pashankar, MD, director of Yale Medicine’s Pediatric IBD Program, provides modern diagnostic and therapeutic options for children with inflammatory bowel disease (IBD), gastrointestinal and nutritional disorders. “We are a part of a quality improvement network for children with inflammatory bowel diseases and our remission rates are excellent,” Dr. Pashankar says. “We are able to treat our patients better with new medications and can avoid surgery.”
Dr. Pashankar says one of his most memorable patients was very sick and had been referred for surgery by another doctor. “We treated her with a combination of medical and nutritional therapy and she recovered,” he says. “She is in college now and doing very well.” Dr. Pashankar is an associate professor of pediatrics (gastroenterology) at Yale School of Medicine.
Clinical Specialties
Fact Sheets
Pediatric Crohn's Disease
Learn More on Yale MedicinePediatric Ulcerative Colitis
Learn More on Yale MedicineAbdominal Migraine: Symptoms, Diagnosis & Treatment
Learn More on Yale MedicineAbdominal Pain
Learn More on Yale Medicine
Board Certifications
Pediatric Gastroenterology
- Certification Organization
- AB of Pediatrics
- Latest Certification Date
- 2015
- Original Certification Date
- 2007
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
- November 18, 2024
Implementing eConsult Program Strategies Highlighted in PLOS One
- April 17, 2023
Stopping CAUTIs, CLABSIs, COVID, and More
- June 02, 2020Source: Connecticut Mag
Connecticut's Best Doctors 2020
- June 14, 2019
Over 200 Yale Medicine Physicians Make 2019 ‘Best Doctors’ List
Get In Touch
Contacts
Pediatric Gastroenterology & Hepatology
333 Cedar Street, PO Box 208064
New Haven, CT 06520-8064
United States
Locations
Pediatric GI/Hepatology
Academic Office
Laboratory for Medicine and Pediatrics (LMP)
15 York Street, Ste 4093
New Haven, CT 06510
Fax
203.737.1384Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.